Gibson Dunn Advises BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics
In relation to a $400 million senior secured term loan arrangement that partially funded the purchase of Astria Therapeutics, Inc., Gibson Dunn represented BioCryst Pharmaceuticals, Inc.